Profile
ACST NVO VRTX REGN MRNA SGEN
Company Name Acasti Pharma Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $26.69M $579.91B $126.85B $115.26B $46.43B $43.15B
Employees 0.03K 66.02K 5.40K 13.68K 5.60K 3.26K
CEO Mr. Prashant Kohli Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
ACST NVO VRTX REGN MRNA SGEN
Quant Rating Score 3 5 4 4 3 3
Quant Rating Neutral Strong Buy Buy Buy Neutral Neutral
Trading
ACST NVO VRTX REGN MRNA SGEN
Last Close $2.84 $131.54 $491.57 $1063.6 $121.14 $228.74
High 52 $3.45 $199.54 $492.13 $1100.05 $166.61 $228.9
Low 52 $1.77 $87.78 $340.48 $727.13 $69.51 $191.57
Price vs. 52 Week High -17.68 % -34.08 % -0.11 % -3.31 % -27.29 % -0.07 %
Price vs. 52 Week Low 60.45 % 49.85 % 44.38 % 46.27 % 74.28 % 19.4 %
Total Return
ACST NVO VRTX REGN MRNA SGEN
1 Month Return -13.94 % -7.34 % 4.88 % 0.99 % -9.19 % 0 %
3 Month Return -0.35 % 5.01 % 22.92 % 18.16 % 15.97 % 0 %
6 Month Return 20.34 % 24.69 % 11.69 % 12.81 % 21.5 % 0 %
9 Month Return 16.87 % 36.61 % 35.85 % 31.56 % 50.67 % 6.14 %
YTD Return -1.73 % 27.15 % 20.81 % 21.1 % 21.81 % 0 %
1 Year Return 11.8 % -20.6 % 35.62 % 44.78 % -4.18 % 17.51 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACST NVO VRTX REGN MRNA SGEN
Dividend Yield Percentage (TTM) - 0.15 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -564.43 % 1.1 % 8.49 % 6.2 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
ACST NVO VRTX REGN MRNA SGEN
Asset Growth -7.36 % 30.35 % 25.23 % 13.23 % -28.74 % -1.21 %
Gross Profit Growth 99.98 % 32.32 % 9.25 % 6.49 % -85.12 % 22.93 %
Revenue Growth - 31.26 % 10.17 % 7.76 % -64.94 % 24.65 %
Revenue 3 Year -100 % 90.51 % 59.87 % 55.67 % 2356.27 % 91.84 %
Revenue 5 Year - 124.2 % 218.58 % 110.3 % 1070.62 % 215.48 %
Revenue 10 Year -100 % 66.11 % 608.27 % 549.62 % 6447.35 % 494.04 %
EBIT Growth -171.95 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Net Income Growth 69.71 % 50.71 % 8.96 % -8.87 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share 83.06 % 106.79 % 34.59 % 13.48 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share 79.13 % 133.86 % 70.33 % 74.02 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share 77.44 % 98.61 % 809.6 % 871.12 % -2046.03 % -624.16 %
Operating Income Growth -171.95 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) 22.5 % 38.06 % -14.35 % -8.39 % -162.6 % 9.07 %
Operating 3 Year CFG 77.66 % 118.29 % 9.63 % 76.95 % -253.56 % -148.34 %
Operating 5 Year CFG 63.89 % 163.51 % 174.78 % 125.17 % -100.11 % -195.86 %
Operating 10 Year CFG 95.02 % 150.92 % 6084.35 % 713.56 % -4698.89 % -2622.09 %
EPS Growth 76.36 % 52.28 % 8.33 % -8.54 % -158.15 % 10.81 %
EPS Diluted Growth 76.36 % 52.37 % 8.35 % -9.03 % -161.39 % 10.81 %
Book Value Per Share -29.1 % 29 % 25.58 % 15.03 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -71.23 % 75.22 % 104.06 % 137.56 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share 320.5 % 121.9 % 291.14 % 219.1 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -94.6 % 49.62 % 1030.79 % 1286.9 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - 80.03 % - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -100 % 4.74 % 44.1 % 0.06 % 3.58 % -23.28 %
Free Cash Flow Growth 22.44 % 9.17 % -16.47 % -17.11 % -183.5 % 3.67 %
Updated On 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
ACST NVO VRTX REGN MRNA SGEN
Gross Profit Margin TTM - 84.65 % 86.86 % 87.16 % 21.77 % 75.4 %
Return on Assets TTM -18.14 % 29.87 % 16.81 % 11.22 % -35.67 % -20.64 %
Return on Equity TTM -20.68 % 91.82 % 23.61 % 15.15 % -41.83 % -28.06 %
Return on Capital Employed TTM -20.75 % 82.5 % 20.67 % 12.53 % -35.81 % -29.5 %
Net Income Per EBT TTM 90.56 % 79.81 % 84.31 % 95.44 % 124.28 % 101.53 %
EBT Per Ebit TTM 98.84 % 101.7 % 114.62 % 104.74 % 93.44 % 93.47 %
EBIT Per Revenue TTM - 45.03 % 40.85 % 29.46 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM - 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Receivables Turnover TTM - 3.87 5.68 2.51 13.32 3.64
Payables Turnover TTM 9.52 2.88 3.81 2.51 22.04 2.52
Inventory Turnover TTM - 1.12 1.65 0.62 13.67 1.07
Fixed Asset Turnover TTM - 248.64 % 685.31 % 310.02 % 186.78 % 471.71 %
Asset Turnover TTM - 81.71 % 42.57 % 38.12 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -1.32 20.95 15.27 43.96 -7.54 -2.87
Free Cash Flow Per Share TTM -1.32 11.28 13.48 36.87 -9.61 -3.73
Cash Per Share TTM 244.75 % 208.61 % 3939.31 % 9758.35 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM - 38.24 % 38.74 % 36.17 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.18 % 53.85 % 88.22 % 83.87 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM - 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM -2.15 78.98 36.46 29 -12.64 -61.54
Price To Operating Cash Flows Ratio TTM -2.15 43.03 32.18 24.19 -16.06 -79.67
Price Cash Flow Ratio TTM -2.15 43.03 32.18 24.19 -16.06 -79.67
Income Statement (TTM)
ACST NVO VRTX REGN MRNA SGEN
Revenue $0B $232.26B $9.84B $13.12B $6.75B $1.96B
Gross Profit $-0B $196.5B $8.58B $11.3B $2.06B $1.55B
Gross Profit Ratio 0% 84.6% 87.17% 86.16% 30.52% 79.1%
EBITDA $-0.01B $112.94B $3.93B $5.13B $-3.21B $-0.62B
Net Income $-0.01B $83.68B $3.62B $3.95B $-4.71B $-0.61B
EPS Diluted -1.35 18.62 13.89 34.77 -12.34 -3.3
Balance Sheet (MRQ)
ACST NVO VRTX REGN MRNA SGEN
Long Term Debt $0B $20.53B $0.72B $2.7B $1.22B $0.04B
Total Liabilities $0.01B $207.93B $5.15B $7.11B $4.57B $0.87B
Total Equity $0.06B $106.56B $17.58B $25.97B $13.85B $2.8B
Total Investments $0B $17.5B $3.45B $13.51B $4.68B $1.42B
Total Debt $0B $27.01B $0.81B $2.7B $1.24B $0.04B
Total Assets $0.07B $314.49B $22.73B $33.08B $18.43B $3.67B
Cash Flow Statement (TTM)
ACST NVO VRTX REGN MRNA SGEN
Net Income $-0.01B $83.68B $3.62B $3.95B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.32B $-0.27B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $108.91B $3.54B $4.59B $-3.12B $-0.45B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.43
ABCL AbCellera Biologics Inc. 2.97
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.11
ABIO ARCA biopharma, Inc. 3.285
ABOS Acumen Pharmaceuticals, Inc. 2.87
ABSI Absci Corporation 3.97
ABUS Arbutus Biopharma Corporation 3.69
ABVC ABVC BioPharma, Inc. 0.826
ABVX Abivax SA American Depositary Shares 12.4
ACAD ACADIA Pharmaceuticals Inc. 17.75
ACER Acer Therapeutics Inc. 0.9
ACET Adicet Bio, Inc. 1.24
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.8352
ACHV Achieve Life Sciences, Inc. 4.63
ACIU AC Immune SA 3.48
ACLX Arcellx, Inc. 62.56
ACRV Acrivon Therapeutics, Inc. Common Stock 7.33
ACXP Acurx Pharmaceuticals, Inc. 2.43
Unlock